Medicine
Poteligeo 20 mg/5 mL injection
Poteligeo 20 mg/5 mL injection is a prescription medicine containing Mogamulizumab for intravenous use, marketed by Kyowa Kirin, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in original…
Key facts
- Active ingredient (INN)
- Mogamulizumab
- Brand
- Poteligeo
- Strength
- 20 mg/5 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 5 mL
- Marketing authorisation holder
- Kyowa Kirin
- Manufacturer
- Kyowa Kirin
- Origin register
- US FDA, United States
- Storage
- Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in original package to protect from light until time of use. Do not freeze. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FX09 Mogamulizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 August 2018
- Identifiers
- RxCUI 2054081, 2054086DailyMed set ID e53960ab-42a1-40d1-9c7d-eb013fe7f18fNDC 42747-761Application BLA761051
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 5 mL in 1 vial, glass | 42747-761-01 | Kyowa Kirin | 8 August 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Mogamulizumab is a chemokine receptor type 4 interaction indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. MedsAcross supplies Mogamulizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MogamulizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- POTELIGEO prescribing information (Kyowa Kirin) · U.S. National Library of Medicine, DailyMed
- Poteligeo: European public assessment report (EPAR) · European Medicines Agency
Need Poteligeo 20 mg/5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.